Pharmacology remains one of the most challenging and high-stakes components of clinical practice and board certification. For Physician Assistants (PAs) managing complex patient populations, staying current on drug interactions, mechanisms of action, and new therapeutic guidelines is a professional necessity. Our Pharmacology CME Review Course has become the preferred choice for PAs seeking high-yield clinical content paired with unparalleled convenience.
Logistical Details:
- Price: Starting at $399.99
- Duration of Access: 30 Months
- Deliverables: 120 Pharmacology Practice Questions
- Credits: 12 AAPA Category 1 Self-Assessment CME Credits
The Demand for High-Quality Pharmacology CME
The modern clinical environment requires PAs to be experts in polypharmacy and medication management. Our course was designed by physician assistants for physician assistants to address this specific need. Unlike generic CME, this curriculum focuses on the clinical application of pharmacological principles in primary care, emergency medicine, and internal medicine.
AAPA Category 1 Credit and NCCPA Weighting
A significant reason for the popularity of this course is the credit structure. This course provides 12 AAPA Category 1 Self-Assessment CME credits. For PAs maintaining NCCPA certification, self-assessment credits are particularly valuable because the NCCPA applies an additional 50% weighting to these credits. This means your 12 hours of effort effectively count for 18 hours when logged for certification maintenance.
Another major reason PAs are choosing this course right now is the June 30th deadline many are working against for license renewal, employer CME cutoff dates, and mid-year compliance tracking. If you need pharmacology CME completed before the end of June, a focused self-assessment course with immediate educational value is a practical option.
While our PANRE Review Course provides 100 hours of AAPA Category 1 credit, the Pharmacology course is specifically tailored to meet prescriptive authority requirements that many states mandate for license renewal.
Unmatched Convenience: CME with Gift Card Add-Ons
We recognize that PAs are busy professionals who need to maximize the value of their CME stipend. To support further educational enrichment, we offer CME with Amazon and Apple Gift Card add-ons.
Purchasers can choose to add a gift card ranging from $100 to $1500 to their purchase. This allows you to secure your required credits while also obtaining the funds needed for additional medical equipment, textbooks, or technology to enhance your practice. This "one-stop-shop" approach simplifies the procurement process and ensures you are making the most efficient use of your annual CME budget.
Clinical Application and Content Breadth
The content is not just a list of drug classes. It covers essential topics across:
- Emergency Medicine
- Family Medicine
- Internal Medicine
- Orthopedics
- Dermatology
- Psychiatry
- Neurology
- Cardiology
- OB/GYN
This breadth ensures that regardless of your specialty, the pharmacology principles discussed are relevant to your daily patient interactions. For those preparing for the NCCPA exams, this content aligns with the expectations found in the NCCPA Blueprint.
Clinical Vignette: Pharmacology Practice Question
Your patient is a 64-year-old male with a history of chronic heart failure (HFrEF, EF 30%) and chronic kidney disease (Stage 3). He is currently taking Lisinopril 20mg daily, Carvedilol 12.5mg BID, and Furosemide 40mg daily. He presents for a follow-up with a stable blood pressure of 128/78 mmHg and a heart rate of 62 bpm. His laboratory results today show a serum potassium of 4.8 mEq/L and a Creatinine of 1.6 mg/dL (Baseline 1.5 mg/dL). According to the current heart failure guidelines, which of the following is the most appropriate next step in his pharmacological management to reduce mortality?
A) Increase Carvedilol to 25mg BID
B) Add Spironolactone 12.5mg daily
C) Switch Lisinopril to Sacubitril/Valsartan
D) Add Amlodipine 5mg daily
Correct Answer: C) Switch Lisinopril to Sacubitril/Valsartan
Switching to an Angiotensin Receptor-Neprilysin Inhibitor (ARNI) like Sacubitril/Valsartan is the correct choice. Current clinical guidelines for HFrEF recommend replacing an ACE inhibitor or ARB with an ARNI in symptomatic patients to further reduce morbidity and mortality. The patient’s blood pressure and potassium levels are within a range that allows for this transition, provided a 36-hour washout period is observed if switching from an ACE inhibitor.
- A) Increase Carvedilol: While titrating beta-blockers to the maximum tolerated dose is important, his heart rate is already 62 bpm, suggesting limited room for further titration without causing bradycardia.
- B) Add Spironolactone: Mineralocorticoid receptor antagonists (MRAs) also reduce mortality; however, switching to an ARNI is generally prioritized in stable patients already on an ACEi/ARB before adding further diuretics, especially with CKD concerns, though both are viable steps.
- D) Add Amlodipine: Calcium channel blockers like amlodipine do not provide the same mortality benefit in HFrEF as ARNIs and are not first-line for this purpose.
Secure Your Credits Today
Whether you are preparing for the PANRE, fulfilling state pharmacology requirements, or simply aiming to sharpen your clinical knowledge, our courses provide the quality you need with the convenience you want.
Join the thousands of PAs, NPs, and physicians who have utilized our CME Review Courses to advance their education. Secure your 12 hours of Pharmacology Category 1 Self-Assessment credit or your 100 hours of PANRE Review credit today.